OCompany · Healthtech & Bio
Orikine Bio
Orikine Bio is a Barcelona-based biotech spin-off from the Centre for Genomic Regulation (CRG) that designs precision-engineered, bi-specific cytokines (its proprietary Foldikine platform) to treat autoimmune and inflammatory immune-mediated diseases. Founded in 2022, it closed a €5.5M seed round led by Sabadell Asabys and AdBio Partners, and has added public non-dilutive funding including CDTI/INNVIERTE, NEOTEC (€335k) and a €800k CPP23 award. It is headquartered in the Barcelona Science Park.
Founded
2022
Founders
4
News
6
Rounds
1
Investors
3
SectorsBiotech, Therapeutics, Immunology, Protein Engineering, Healthtech & Bio
Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers
Profile updated 7 Sep 2026
Founders
A
Alejo Chorny
Co-Founder & Former CEO
A
Ariadna Montero Blay
Scientific Founder & Head of Biology
—
J
Javier Delgado
Scientific Founder & Advisor
—
L
Luis Serrano
Scientific Founder & Advisor
—
Global models
No comparables on record yet.
Investors 3
Funding rounds 1
News & media 6
| Published | Article |
|---|---|
| 2026-05-13 |
Christian Pangratz, CEO of Orikine Bio: "We're advancing from research into preclinical development to address a specific type of inflammation that underlies severe inflammatory diseases" ↗
Parc Científic de Barcelona
|
| 2026-02-02 |
Orikine Bio receives €2.7M in investment from CDTI Innovación together with two other investors ↗
Parc Científic de Barcelona
|
| 2026-01-20 |
Orikine Bio appoints Larry Edwards as Chairman of the Board ↗
Parc Científic de Barcelona
|
| 2026-01-14 |
Orikine Bio settles in the Science Park to advance the design of innovative immunotherapies ↗
Parc Científic de Barcelona
|
| 2024-12-04 |
Orikine Bio secures €800k in innovation research funding to advance groundbreaking autoimmune disease therapy ↗
BioSpace
|
| 2024-11-04 |
Barcelona's fresh wave of innovation: 10 early-stage startups to keep an eye on ↗
EU-Startups
|